Nautilus Biotechnology, Inc.
NASDAQ:NAUTBiotechnology
+$0.05 today
- Market cap
- $309.51M
- Beta
- 0.75
- P/E (TTM)
- -4.9
- EPS (TTM)
- -$0.45
Volume 4.55M
Average 0.40M
NAUT Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Nautilus Biotechnology, Inc.NASDAQ: NAUT
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization declines year over year
Q1 FY2026 depreciation & amortization of $1.48M fell 9.2% year over year, behind the -1.1% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 7.1% from the prior quarter. Over 3 fiscal years it compounded at +23.7% a year.
Context
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -9.2% toward the trailing-twelve-month pace of -1.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 6.47M USD
- Year-over-year change
- +1.8%
- 4-year CAGR
- +22.8%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 6.47M | +1.8% |
| FY2024 | 2024-12-31 | 6.35M | +11.4% |
| FY2023 | 2023-12-31 | 5.71M | +67.0% |
| FY2022 | 2022-12-31 | 3.42M | +20.2% |
| FY2021 | 2021-12-31 | 2.84M | — |
Depreciation & Amortization vs competitors
How NAUT compares with its peers on the latest reported figures
- NAUT's LTM Mar 2026 depreciation & amortization of $6.32M is the 3rd largest of the 11 companies compared; the peer median is $2.86M.
- Its year-over-year change of -1.1% is the 6th highest of 10, against a peer median of +15.1%.
- Over three fiscal years its annual growth of +23.7% compares with a peer median of +3.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $7.81M | -13.0% | +11.0% | 3469.8% | |
| LTM Mar 2026 | $6.86M | +34.4% | -13.4% | 340.1% | |
| LTM Mar 2026 | $6.32M | -1.1% | +23.7% | — | |
| LTM Mar 2026 | $4.95M | +56.5% | +19.6% | 7.2% | |
| LTM Mar 2026 | $4.42M | +82.7% | +85.3% | 31.9% | |
| LTM Mar 2026 | $2.88M | -16.2% | +25.6% | 6.4% | |
| LTM Mar 2026 | $2.84M | -8.0% | -25.0% | 10.1% | |
| LTM Mar 2026 | $531.13K | +15.1% | -4.3% | — | |
| LTM Mar 2026 | $122K | -6.2% | -36.3% | 0.2% | |
ZURAZura Bio Limited | LTM Mar 2026 | $56K | +229.4% | — | — |
SGMTSagimet Biosciences Inc. | LTM Mar 2026 | $0 | — | — | — |
| Peer median (excluding NAUT) | $2.86M | +15.1% | +3.4% | 10.1% | |
Competitors are the stored peer set for NAUT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (50.32M) | (57.92M) | (63.68M) | (70.78M) | (59M) |
| Depreciation & Amortization | 2.84M | 3.42M | 5.71M | 6.35M | 6.47M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 7.93M | 10.38M | 12.14M | 12.7M | 6.84M |
| Change in Working Capital | (22K) | (788K) | (3.22M) | (5.46M) | (3.58M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.26M | (561K) | 393K | (578K) | (69K) |
| Other Working Capital | (1.28M) | (227K) | (3.61M) | (4.88M) | (3.52M) |
| Other Non-Cash Items | 320K | (890K) | (2.66M) | (1.96M) | (1.42M) |
| Operating Cash Flow | (39.24M) | (45.81M) | (51.71M) | (59.15M) | (50.7M) |
| Capital Expenditures | (2.27M) | (2.32M) | (2.44M) | (2.12M) | (1.28M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (221.8M) | (186.59M) | (112.89M) | (86.28M) | (72.49M) |
| Sales of Investments | 85.1M | 163.18M | 71.6M | 155.41M | 108.99M |
| Other Investing Activities | 0 | 0 | 0 | (760K) | 0 |
| Investing Cash Flow | (138.96M) | (25.74M) | (43.74M) | 66.25M | 35.22M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | (7.96M) | 562K | 368K | 1.14M | 214K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 335.41M | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 327.45M | 562K | 368K | 1.14M | 214K |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 149.24M | (70.98M) | (95.08M) | 8.25M | (15.26M) |
| Free Cash Flow | (41.51M) | (48.13M) | (54.15M) | (61.27M) | (51.97M) |
Nautilus Biotechnology, Inc.
NASDAQ:NAUT
Intrinsic Alpha fair value
Locked
Current Price
$2.43
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.